Brind.

Incyte begins Phase III clinical trial for vitiligo drug in China

1 report, 1 independent Updated 12:45
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Incyte is conducting a multi-center, randomized, double-blind, placebo-controlled Phase III clinical study in Shenzhen, China. The trial evaluates the efficacy and safety of povorcitinib in Chinese adult patients with non-segmental vitiligo. The study is planned for approximately 44 clinical research centers across China and aims to enroll about 174 patients. The drug has previously been certified as a Breakthrough Therapeutic Drug by the National Medical Products Administration of the People’s Republic of China.

From briefingwire.com

Why it matters

Some supportBrind's analysis of the reports

The enrollment of the first patient marks a key stage in the drug’s clinical evaluation in China. The Breakthrough Therapeutic Drug certification from the National Medical Products Administration of the People’s Republic of China may accelerate the drug's development and review process, potentially aiding market access.

From briefingwire.com

Who's involved

  • IncyteAmerican pharmaceutical company conducting the clinical trials
  • ShenzhenCity in China where the clinical trials are taking place

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped